Immunotherapy Bapineuzumab Humanized 3D-6 Monoclonal Antibody Pharmacologic Substance Amino Acid, Peptide, or Protein NC11WKO35D BAPINEUZUMAB C2698328 A humanized monoclonal antibody (IgG1) raised against amyloid beta peptides with Alzheimer disease treatment application. Bapineuzumab recognizes and binds the N-terminal amino acids 1-5 of the amyloid beta peptide, and may be used in a passive immunotherapy treatment. AAB-001 FDA 648895-38-9 C79569 Alzheimer's disease Bapineuzumab Anti-human beta-amyloid Monoclonal Antibody 3D-6 Bapineuzumab Bapineuzumab